Project Grant R43AI149901

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 11, 2025, through August 31, 2026. The company is developing a microneedle-based messenger RNA (mRNA) flu vaccine candidate designed for transcutaneous (intradermal) immunization. The project leverages Via Therapeutics' proprietary thin-film...

Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $437,541 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and develop antisense therapeutics for treatment of Clostridioides difficile infection (CDI). The award, dated February 2, 2026, with a completion date of January 31, 2028, supports research aimed at creating targeted...

The National Institutes of Health (NIH) has awarded a $1,333,682 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to North Carolina State University (NC State) to develop peptide inhibitors that neutralize bacterial toxins and deliver them using engineered probiotic yeast. This 3-year project aims to expand on NC State's previous work identifying a lead peptide inhibitor of Clostridioides difficile toxin, by screening for inhibitors of 5 additional bacterial toxins. The...

This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...

Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Cooperative Agreement valued at $1.67 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a Phase 1 clinical study of a novel messenger ribonucleic acid (mRNA)-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The research, initiated September 25, 2025, and scheduled for completion by July...

Federal Project Grant Award Summary Antigen Discovery Inc. (ADI), doing business as Immport Therapeutics Inc., received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 12, 2025, with completion targeted for July 31, 2027. The award supports the development and optimization of novel cryptosporidium vaccine candidates through production of purified...

Summary of Federal Project Grant Award Vishenary, LLC received a $308,669 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 23, 2025, with a completion date of March 31, 2027. The grant funds the development of a novel vaccine candidate designed to provide broad protection against nontypeable Haemophilus influenzae (NTHI) infection following influenza A virus...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $364,167 to Villanova University to develop novel non-viral gene delivery methods for cell therapies. The key objectives are: The Bracaglia Lab will develop new polymeric gene delivery vehicles to improve the delivery of siRNAs and other payloads to T cells and hematopoietic stem cells (HSCs). Drs. Elmer and Huang will...

Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $458,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 4, 2025, with a completion date of August 31, 2027. The project, titled "A VP4-Based Pseudovirus Nanoparticle Rotavirus Vaccine for Oral Immunization," focuses on developing a non-replicating rotavirus...